Evidence map›Paper›PMID 24332862›Full record

ArticleThe Journal of allergy and clinical immunology2014

Case fatality and population mortality associated with anaphylaxis in the United States.

Larry Ma, Theodore M Danoff, Larry Borish

Abstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it, 241 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Using Biologics in the Prevention of Anaphylaxis.Current allergy and asthma reports · 2025
    Review
  11. Lactate in Anaphylaxis: 100 Years On.Sports medicine (Auckland, N.Z.) · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Emergency Monitoring Following A Diagnosis of Anaphylaxis.Current allergy and asthma reports · 2025
    Review
  16. Cost-effectiveness of watchful waiting versus immediate emergency department transfer after epinephrine autoinjector use in Canada.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
  17. Article
  18. Observational
  19. Anaphylaxis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024
    Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Larry MaEndo Pharmaceuticals Inc, Malvern, Pa. Electronic address: ma.larry@endo.com.
Theodore M DanoffEndo Pharmaceuticals Inc, Malvern, Pa.
Larry BorishAsthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, Va.
Endo Pharmaceuticals (United States) · USUniversity of Virginia Health System · US

Funding

An Evaluation of Treatment with Omalizumab to Improve the Asthmatic Response to aU01AI100799 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYMANN, PETER W, PLATTS-MILLS, THOMAS A. · 2012 to 2015
$5.3M
Interplay between LTE4/LTE4 receptors and IFN-y with mast cells and eosinophils iR01AI057438 · NIAID · UNIVERSITY OF VIRGINIA · PI BORISH, LARRY C · 2006 to 2015
$3.7M
NIAID NIH HHS R01 AI057438NIAID NIH HHS R01 AI1057438NIAID NIH HHS U01 AI100799NIAID NIH HHS UO1 AI100799
6 · The paper itself

Abstract

backgroundAnaphylaxis is a serious allergic reaction that can cause death; however, the actual risk of death is unclear.

objectiveWe sought to estimate the case fatality rate among hospitalizations or emergency department (ED) presentations for anaphylaxis and the mortality rate associated with anaphylaxis for the general population.

methodsThis was a population-based epidemiologic study using 3 national databases: the Nationwide Inpatient Sample (NIS; 1999-2009), the Nationwide Emergency Department Sample (NEDS; 2006-2009), and Multiple Cause of Death Data (MCDD; 1999-2009). Sources for these databases are hospital and ED discharge records and death certificates, respectively.

resultsCase fatality rates were between 0.25% and 0.33% among hospitalizations or ED presentations with anaphylaxis as the principal diagnosis (NIS+NEDS, 2006-2009). These rates represent 63 to 99 deaths per year in the United States, approximately 77% of which occurred in hospitalized patients. The rate of anaphylaxis-related hospitalizations increased from 21.0 to 25.1 per million population between 1999 and 2009 (annual percentage change, 2.23%; 95% CI, 1.52% to 2.94%), contrasting with a decreasing case fatality rate among hospitalizations (annual percentage change, -2.35%; 95% CI, -4.98% to 0.34%). Overall mortality rates ranged from 0.63 to 0.76 per million population (186-225 deaths per year, MCDD) and appeared stable in the last decade (annual percentage change, -0.31%; 95% CI, -1.54% to 0.93%).

conclusionFrom 2006 to 2009, the overwhelming majority of hospitalizations or ED presentations for anaphylaxis did not result in death, with an average case fatality rate of 0.3%. Anaphylaxis-related hospitalizations increased steadily in the last decade (1999-2009), but this increase was offset by the decreasing case fatality rate among those hospitalized; both inpatient and overall mortality rates associated with anaphylaxis appeared stable and were well under 1 per million population. Although anaphylactic reactions are potentially life-threatening, the probability of dying is actually very low. With the prevalence of anaphylaxis on the increase, practitioners need to stay vigilant and follow the treatment guidelines to further reduce anaphylaxis-related deaths.

Indexed as

AdolescentAdultAgedAged, 80 and overAnaphylaxisChildChild, PreschoolDatabases, FactualFemaleHospitalizationHospital MortalityHumansInfantInfant, NewbornMaleMiddle AgedAnaphylaxiscase fatalitydeath certificateemergency department presentationepidemiologyhospitalizationmortality

Identifiers

PMID24332862
PMCPMC3972293
OpenAlexW2055794022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.